Basaglar and Venclexta drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Basaglar (insulin glargine) and Venclexta (venetoclax). Common drug interactions include death among females and death among males.

The phase IV clinical study analyzes what interactions people have when they take Basaglar and Venclexta. It is created by eHealthMe based on reports of 30 people who take the same drugs from the FDA, and is updated regularly.

What is Basaglar?

Basaglar has active ingredients of insulin glargine. eHealthMe is studying from 19,807 Basaglar users. Check the latest studies of Basaglar.

What is Venclexta?

Venclexta has active ingredients of venetoclax. eHealthMe is studying from 31,425 Venclexta users. Check the latest studies of Venclexta.

On Apr, 29, 2026

30 people who take Basaglar and Venclexta together, and have interactions are studied.

Basaglar and Venclexta drug interactions.

What are the common drug interactions of Basaglar and Venclexta, by gender? *:

female:

Death

male:

Death
Asthenia (weakness)
Weight decreased
Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
Infection
Blood immunoglobulin g decreased
Chemotherapy
Haemolytic anaemia (anaemia due to haemolysis)
Lymphadenopathy (disease or enlargement of lymph nodes)
Muscle atrophy (a decrease in the mass of the muscle)

What are the common drug interactions of Basaglar and Venclexta, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Thrombosis (formation of a blood clot inside a blood vessel)

50-59:

Blood immunoglobulin g decreased
Haemolytic anaemia (anaemia due to haemolysis)
Lymphadenopathy (disease or enlargement of lymph nodes)
Muscle atrophy (a decrease in the mass of the muscle)
Weight decreased
Constipation
Dizziness
Fall
Hallucination (an experience involving the perception of something not present)
Urinary incontinence (inability to control the flow of urine and involuntary urination)

60+:

Death
Bacterial infection
Infection
Visual acuity reduced (reduced clearness of vision)
Weight decreased
White blood cell count decreased
Haemorrhage (bleeding)
Heart rate decreased
Pleural effusion (water on the lungs)
Renal impairment (severely reduced kidney function)

What are the existing conditions these people have? *

Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 14 people, 46.67%
Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 8 people, 26.67%
Diabetes: 4 people, 13.33%
Lymphocytic Leukaemia (a type of cancer in which the bone marrow makes too many lymphocytes): 2 people, 6.67%
Hypersensitivity: 2 people, 6.67%
High Blood Pressure: 2 people, 6.67%
Gout (uric acid crystals building up in the body): 2 people, 6.67%
Constipation: 2 people, 6.67%
Cardiac Disorder: 2 people, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Basaglar and Venclexta?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously